共临床试药验证多韦替尼(一种FGFR抑制剂)在肺鳞状细胞癌中的预测性生物标志物
在肺鳞状细胞癌(LSCC)中开展共临床试药,用5例患者来源异种移植(PDX)模型(PDX01-02来自II期多韦替尼试验入组患者,PDX03-05来自接受手术患者)进行体内药效测试、全外显子测序和基因表达谱分析。多韦替尼在PDX-01和PDX-05中引起显著肿瘤退缩,在PDX-02中导致肿瘤进展,与试验入组患者的临床结局一致;FGFR1-3基因组改变与多韦替尼敏感性无相关性,而FGFR信号通路基因表达特征(包括FGF3、FGF19及18个关键信号组分)可预测多韦替尼敏感性。
要点
- PDX-01和PDX-05对多韦替尼敏感并显著退缩,PDX-02、03、04疗效差,与临床试验患者结局一致。
- FGFR1-3基因组改变与多韦替尼敏感性无相关性。
- FGFR配体结合/激活和SHC介导级联通路在敏感PDX中上调,可预测多韦替尼敏感性。
核心结论
- FGFR基因表达特征可预测肺鳞状细胞癌对多韦替尼的应答。
研究设计与样本
- 在肺鳞状细胞癌患者来源异种移植(PDX)模型中开展共临床试药,以识别多韦替尼的预测性生物标志物。
- PDX01-02建立自多韦替尼II期试验(NCT01861197)入组的肺鳞状细胞癌患者,PDX03-05建立自接受手术的肺鳞状细胞癌患者。
- 对这5例PDX肿瘤进行多韦替尼体内药效测试、全外显子测序和基因表达谱分析。
主要发现
- PDX肿瘤再现了原发肿瘤的组织病理学特征并维持其基因组特征。
- 与试验入组肺鳞状细胞癌患者的临床结局一致,多韦替尼使PDX-01和PDX-05肿瘤显著退缩,而导致PDX-02肿瘤进展。
- PDX-03和PDX-04对多韦替尼也显示较差的抗肿瘤疗效。
- 突变和全基因组拷贝数谱显示FGFR1-3的基因组改变与多韦替尼敏感性之间无相关性。
- 基因表达谱显示PDX-01和05与PDX-02-04之间差异表达基因包括FGF3和FGF19。
关键数值与推荐
- FGFR配体结合/激活和SHC介导级联通路在敏感PDX(PDX-01和05)中较 resistant PDX(PDX-02-04)显著上调。
- FGFR通路中18个关键信号组分的转录激活可预测细胞系和PDX肿瘤对多韦替尼的敏感性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We conducted co-clinical trials in patient-derived xenograft (PDX) models to identify predictive biomarkers for the multikinase inhibitor dovitinib in lung squamous cell carcinoma (LSCC). METHODS: The PDX01-02 were established from LSCC patients enrolled in the phase II trial of dovitinib (NCT01861197) and PDX03-05 were established from LSCC patients receiving surgery. These five PDX tumors were subjected to in vivo test of dovitinib efficacy, whole exome sequencing and gene expression profiling. RESULTS: The PDX tumors recapitulate histopathological properties and maintain genomic characteristics of originating tumors. Concordant with clinical outcomes of the trial enrolled-LSCC patients, dovitinib produced substantial tumor regression in PDX-01 and PDX-05, whereas it resulted in tumor progression in PDX-02. PDX-03 and -04 also displayed poor antitumor efficacy to dovitinib. Mutational and genome-wide copy number profiles revealed no correlation between genomic alterations of FGFR1-3 and sensitivity to dovitinib. Of note, gene expression profiles revealed differentially expressed genes including FGF3 and FGF19 between PDX-01 and 05 and PDX-02-04. Pathway analysis identified two FGFR signaling-related gene sets, FGFR ligand binding/activation and SHC-mediated cascade pathway were substantially up-regulated in PDX-01 and 05, compared with PDX-02-04. The comparison of gene expression profiles between dovitinib-sensitive versus -resistant lung cancer cell lines in the Cancer Cell Line Encyclopedia database also found that transcriptional activation of 18 key signaling components in FGFR pathways can predict the sensitivity to dovitinib both in cell lines and PDX tumors. These results highlight FGFR pathway activation as a key molecular determinant for sensitivity to dovitinib. CONCLUSIONS: FGFR gene expression signatures are predictors for the response to dovitinib in LSCC.
引用
- Kim HR, Kang HN, Shim HS, et al. Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma. Ann Oncol. 2017. PMID: 28460066. doi:10.1093/annonc/mdx098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。